Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Brain Metastases from Genito-Urinary Cancers in the Canton of Geneva (Switzerland): Study of Incidence, Management and Outcomes.
Cancers (Basel)
October 2024
Department of Medical Oncology, Gustave Roussy Cancer Campus, 94805 Villejuif, France.
Background: Incidence of brain metastases is precisely unknown and there is no clear consensus on their management. We aimed to determine the incidence of brain metastases among patients with genito-urinary primaries, present patients' characteristics and identify prognostic factors.
Method: We identified 51 patients treated in Geneva University Hospitals between January 1992 and December 2019.
External validation of the MiGUTS nomogram for the prediction of bleeding control intervention after renal trauma.
World J Urol
September 2024
Department of Urology, Kantonsspital Graubünden, Loëstrasse 170, Chur, CH-7000, Switzerland.
Introduction: The American Association for the Surgery of Trauma (AAST) renal trauma grading leads to a variable management of patients with high-grade renal injuries. For a better prediction of the risk for bleeding interventions, Keihani et al. introduced the multi-institutional genito-urinary trauma study (MiGUTS) renal trauma nomogram in 2019.
View Article and Find Full Text PDFLu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial.
Lancet
September 2024
Gustave Roussy Institute, Paris-Saclay University, Paris, France.
Background: [Lu]Lu-PSMA-617 (Lu-PSMA-617) prolongs radiographic progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer previously treated with androgen receptor pathway inhibitor (ARPI) and taxane therapy. We aimed to investigate the efficacy of Lu-PSMA-617 in patients with taxane-naive metastatic castration-resistant prostate cancer.
Methods: In this phase 3, randomised, controlled trial conducted at 74 sites across Europe and North America, taxane-naive patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who had progressed once on a previous ARPI were randomly allocated (1:1) to open-label, intravenous Lu-PSMA-617 at a dosage of 7·4 GBq (200 mCi) ± 10% once every 6 weeks for six cycles, or a change of ARPI (to abiraterone or enzalutamide, administered orally on a continuous basis per product labelling).
Long-term outcomes of the first prospective study of active surveillance for prostate cancer in Japan.
Int J Clin Oncol
October 2024
Department of Urology, Faculty of Medicine, Kagawa University, 1750-1, Ikenobe, Miki-Cho, Kita-Gun, Kagawa, 761-0793, Japan.
Background: Active surveillance for prostate cancer was initiated in the early 2000s. We assessed the long-term outcomes of active surveillance in Japan.
Methods: This multicenter prospective observational cohort study enrolled men aged 50-80 years with stage cT1cN0M0 prostate cancer in 2002 and 2003.
Bladder Tumor-Focused Adaptive Radiation Therapy: Clinical Outcomes of a Phase I Dose Escalation Study.
Int J Radiat Oncol Biol Phys
January 2025
The Institute of Cancer Research, London, United Kingdom; The Royal Marsden NHS Foundation Trust, London, United Kingdom.
Article Synopsis
- The study aimed to identify the maximum tolerated dose (MTD) for treating muscle invasive bladder cancer using image-guided adaptive radiation therapy while monitoring long-term clinical outcomes.
- A total of 59 patients with specific stages of bladder cancer participated, with their tumors receiving doses ranging from 68 to 72 Gy, and the MTD was found to be 70 Gy.
- Results showed that 5-year overall survival was 58%, and the bladder preservation rate was high at 89%, with minimal severe acute toxicities reported.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!